Recommended Articles
Fundraising

Undecimal Bio Launches With $18M Oversubscribed Seed to Crack the "Liver Trap" in siRNA Delivery

By Angeled · October 13, 2026 · Fundraising
Undecimal Bio Launches With $18M Oversubscribed Seed to Crack the "Liver Trap" in siRNA Delivery
Undecimal Bio Launches With $18M Oversubscribed Seed to Crack the "Liver Trap" in siRNA Delivery

Undecimal Bio, a platform biotechnology company advancing targeted delivery of siRNA therapeutics, announced October 13, 2026 that it has launched with an oversubscribed $18 million seed financing. The round was co-led by 4BIO Capital and IQ Capital, with participation from Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures, and Saras Capital. The company is a spin-out from Eleven Therapeutics, and operates from Cambridge, England and Tel Aviv, Israel.

The funding will expand DELiveri, Undecimal's proprietary AI-enabled platform for identifying conjugates that direct RNA medicines to defined cell types, advance its programs in renovascular disease, and grow the team at its laboratories in the Cancer Research UK Cambridge Institute. Undecimal has also entered several undisclosed research collaborations with big pharma companies.

The "Liver Trap": RNAi's Biggest Unsolved Problem

To appreciate what Undecimal is attempting, you need to understand RNA interference (RNAi). Small interfering RNAs — siRNAs — are short genetic molecules that can switch off specific genes with remarkable precision. The technology has already transformed treatment of diseases caused by genes expressed in the liver: the first approved siRNA drugs work because, conveniently, siRNA delivery vehicles naturally accumulate in the liver.

But that convenience is also a trap. Getting siRNA to work outside the liver — in the kidneys, heart, muscles, or brain — has been one of genetic medicine's defining unsolved problems. The delivery molecule reaches the liver easily and gets stuck there, hence the industry shorthand "liver trap." Whoever cracks extra-hepatic delivery unlocks RNAi for a vastly larger set of diseases.

How DELiveri Works

DELiveri attacks the problem with a combination of massive-scale screening and agentic AI. The platform builds combinatorial libraries of candidate "ligands" — chemical conjugates attached to the siRNA that act as molecular address labels, directing the drug to specific cell types. It then converts cells to act as "molecular radars" that detect productive delivery at single-molecule resolution, generating high-throughput data on which conjugates actually get siRNA inside target cells.

That data is fed to agentic AI systems that decode the structure-activity relationships — essentially learning the chemical grammar of what makes a conjugate work — and score the best candidates. CEO and co-founder Dr. Yaniv Erlich frames it plainly: the hard problem in RNAi was never the silencing, it was getting the molecule to the right cell.

Why Renovascular Disease First

Undecimal is initially applying DELiveri to renovascular diseases — conditions affecting the blood vessels of the kidneys — where clinical need is significant and existing treatments largely address symptoms rather than underlying causes. This is a classic platform-biotech strategy: pick a first indication with a clear unmet need and a tractable path to proof-of-concept, while building a delivery platform that can be licensed or partnered across many indications. The undisclosed big-pharma collaborations suggest that strategy is already working — pharma partners pay for platform access long before a drug reaches the clinic.

The Spin-Out Model and the Investor Syndicate

Undecimal's origins as a spin-out from Eleven Therapeutics reflect a pattern common in biotech: a discovery engine inside one company generates a platform valuable enough to warrant its own entity, management team, and financing. The co-founders are Dr. Yaniv Erlich and Shaul Ilan; the board includes representatives of 4BIO Capital, IQ Capital, and Harel Technologies, with Verve Ventures joining as a board observer.

The syndicate blends deep-tech biotech specialists (4BIO Capital, IQ Capital) with generalist and Israeli tech investors (Entree Capital, Harel Tech) — a mix that gives the company both scientific credibility and commercial reach. An oversubscribed $18M seed is a strong signal in a biotech funding environment that has been selective since the 2021 boom: investors are competing to get into delivery-platform stories.

Why It Matters for Founders and Investors

For founders, Undecimal demonstrates that in biotech, the platform is the pitch: a delivery technology applicable across dozens of programs commands a premium over any single drug asset. For investors, extra-hepatic RNAi delivery is one of the highest-leverage unsolved problems in medicine — a credible platform here carries optionality across the entire genetic-medicine landscape. The oversubscription also confirms that while biotech funding is tighter overall, genuinely differentiated platform technology still attracts competitive capital.

Angeled.com connects founders with investors.

Read Next